An open-label randomized two-arm Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of oral BAY 1217389 in combination with weekly intravenous paclitaxel given in an intermittent dosing schedule in subjects with advanced malignancies

Sponsor
Bayer

Protocol Number
Bayer 17350

To Learn More Call
201-510-0910